Utilization of the smoking cessation medicine varenicline: An intensive post-marketing study in New Zealand

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 9, 2010, Pages 949-953

  Harrison Woolrych, Mira ^a   Ashton, Janelle ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Effectiveness; Post marketing use; Smoking cessation medicines; Utilization; Varenicline

Indexed keywords

VARENICLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; DRUG COSTS; DRUG LABELING; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; NICOTINIC AGONISTS; PRODUCT SURVEILLANCE, POSTMARKETING; QUINOXALINES; SMOKING CESSATION; TIME FACTORS; YOUNG ADULT;

EID: 77957585307     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2003     Document Type: Article

References (12)

1. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179(2): 135-144. DOI: 10.1503/cmaj.070256
2. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release buproprion and placebo for smoking cessation. JAMA 2006; 296: 47-55.
3. Aubin H-J, Britton JR, Oncken C, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 0: 1-8. DOI: 10.1136/thx.2007.090647
4. Pfizer Ltd. New Zealand datasheet for Champix. Available at: http://www.medsafe.govt.nz/profs/datasheets
5. Harrison-Woolrych ML, Coulter DM. PEM in New Zealand. In Pharmacovigilance (2nd edn). Mann R, Andrews EB (eds), John Wiley and Sons: Chichester, England, 2007; 317-332.
6. Kunac DL, Harrison-Woolrych ML, Tatley MV. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. NZ Med J 2008; 121; 1281: 76-89 (available at: www.nzma.org.nz/journal/121-1283/3286)
7. New Zealand Health Information Services (NZHIS). Available at: http://www.moh.govt.nz/moh.nsf/indexmh/dataandstatistics-collections
8. Ministry of Heath. Ethnicity Data Protocols for the Health and Disability Sector. 2004. Wellington, NZ. Available at: www.moh.govt.nz
9. Harrison-Woolrych ML. Psychiatric reactions with varenicline: interim results from intensive monitoring in New Zealand. Prescriber Update 2009; Available at: www.medsafe.govt.nz/profs/PUarticles
10. Moore TJ, Furberg CD. Risk of psychiatric side effects with varenicline. BJM 2009; 339: b4964.
11. Ravva P, Gastonguay MR, French JL, et al. Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin Pharm Ther 2010; 87(3): DOI: 10.1038/clpt.2009.282
12. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010; 25(4): 282-290. DOI: 10.1007/s11606-010-1253-9